{
    "clinical_study": {
        "@rank": "161428", 
        "arm_group": [
            {
                "arm_group_label": "YM060 group", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo group", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate the superiority of YM060 to a placebo in global assessment of relief of\n      overall IBS symptoms and stool form normalization, and to evaluate safety in female patients\n      with diarrhea-predominant irritable bowel syndrome (D-IBS)."
        }, 
        "brief_title": "A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Diarrhea-predominant Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Diarrhea", 
                "Irritable Bowel Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients satisfying the Rome III Diagnostic Criteria\n\n          2. Patients whose \u226525% of stools were loose or watery and <25% of them were hard or\n             lumpy stools\n\n          3. Patients who have abdominal pain or discomfort\n\n          4. Patients in whom after occurrence of IBS symptoms the following tests were conducted\n             and in whom no organic changes were observed Pancolonoscopy or contrast enema\n\n        Exclusion Criteria:\n\n          1. Patients with a history of surgical resection of the stomach, gallbladder, small\n             intestine or large intestine\n\n          2. Patients with a history or current evidence of inflammatory bowel disease\n\n          3. Patients with a history or current evidence of colitis ischemic\n\n          4. Patients with concurrent infectious enteritis\n\n          5. Patients with concurrent hyperthyroidism or hypothyroidism\n\n          6. Patients with concurrent active peptic ulcer\n\n          7. Patients with other concurrent disease that may affect the digestive tract passage or\n             large intestinal function or that is likely to interfere with proper assessment of\n             IBS abdominal pain/discomfort"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "577", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870895", 
            "org_study_id": "060-CL-702"
        }, 
        "intervention": [
            {
                "arm_group_label": "YM060 group", 
                "description": "oral", 
                "intervention_name": "YM060", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ramosetron,", 
                    "Irribow"
                ]
            }, 
            {
                "arm_group_label": "Placebo group", 
                "description": "oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ramosetron"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "YM060", 
            "Ramosetron", 
            "Diarrhea-predominant Irritable Bowel Syndrome"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kantou", 
                        "country": "Japan"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Monthly responder rate of global assessment of relief of overall IBS symptoms at final point", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Monthly responder rate of stool form normalization at final point", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870895"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Monthly responder rate of global assessment of relief of abdominal pain/discomfort", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Monthly responder rate of global assessment of improvement of abnormal bowel habits", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Change in weekly average scores of severity of abdominal pain/discomfort", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Change in weekly average scores of stool form", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Safety assessment of YM060", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}